Latest news with #Actinium-225
Cision Canada
10 hours ago
- Business
- Cision Canada
AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing
HAMILTON, ON, June 17, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie) and TerraPower Isotopes, LLC (TPI) today announced a supply agreement under which TPI will provide its high-quality Actinium-225 (Ac-225) 1 isotope to support AtomVie's contract development and manufacturing (CDMO) activities in radiopharmaceuticals, providing an added value to its clients with Ac-225-based programs. The aim is to strengthen the supply chain and accelerate the development and commercialization of targeted radiopharmaceutical therapies for cancer and other diseases. The agreement supports both AtomVie's early and late-stage development programs with pharmaceutical partners for global clinical and commercial pipelines. By securing a reliable supply of Ac-225, the agreement enhances flexibility and responsiveness across the entire product development lifecycle. "We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie. "Collaborating with AtomVie allows us to help advance the next generation of targeted radiopharmaceutical therapies. By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients." said Scott Claunch, President of TerraPower Isotopes. This supply agreement reflects the shared commitment of both organizations to advancing nuclear medicine innovation and expanding global access to cutting-edge radiotherapies. About AtomVie Global Radiopharma (AtomVie) AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting clinical studies in over 25 countries worldwide. AtomVie is currently building a new state-of-art purpose-built 72,300 sq ft facility, set to launch at the end of 2025. For more information, visit About TerraPower Isotopes (TPI) TerraPower Isotopes is bringing the next generation of isotopes to market. A subsidiary of TerraPower, a leading nuclear innovation company, TerraPower Isotopes applies innovative expertise and proven development methods to targeted alpha therapy. The company supports medical research by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential. TerraPower Isotopes is increasing global access to Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimal damage to healthy tissue. Learn more at About TerraPower TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs. SOURCE AtomVie Global Radiopharma Inc.
Yahoo
4 days ago
- Business
- Yahoo
Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform
BOSTON, June 13, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc. (Macrocyclics) exclusive manufacturing and distribution rights to Ratio's proprietary chelator Macropa™ enabling broad access worldwide. Macropa is a proprietary, best-in-class, bifunctional chelator for Actinium-225 (Ac-225), known for its strong alpha-particle emissions and its use in targeted alpha therapy (TAT) for the treatment of cancer. Macropa can be tethered to small molecules, peptides, and large polypeptides such as proteins and antibodies to enable the development of targeted radiopharmaceuticals for alpha radiotherapy. By rapidly and quantitatively complexing Ac-225 at room temperature, Macropa's unique selectivity and stability for Ac-225 enables simple "one-pot" manufacturing and improves in vivo stability of the resulting compound. "Over the past year, we have been focused on building global scientific awareness and encouraging adoption of our chelator platform across the therapeutic radiopharmaceutical community," said Bill Cupelo, Chief Business Officer of Ratio. "We are proud to see our efforts realized through an expanding global ecosystem of collaborators who can now leverage Macropa to accelerate the development and adoption of radiopharmaceuticals worldwide. By enabling broader access to our platform, we are fostering a global community aligned in the mission to improve patient outcomes through targeted cancer therapies and diagnostics." Incorporated in 1995, Macrocyclics is a CDMO specialized in chelating agents for radiopharmaceuticals and nuclear medicine. The company maintains a broad catalog of bifunctional chelating agents that are used in R&D and clinical programs across the globe. Under the terms of the agreement, researchers from academia and industry may purchase Macropa directly from Macrocyclics, enabling rapid access in many countries including Japan, Canada, Australia and majority of Europe. "Ratio's Macropa is a superior chelator for Ac-225," said Paul Jurek, Ph.D., CEO of Macrocyclics. "The ability to label quickly at room temperature provides a critical advantage, especially when working with proteins or vectors that degrade when heated. We are excited to be the exclusive manufacturer of Macropa and plan to add multiple derivatives to our catalog and provide it under GMP conditions for innovators engaged in clinical research." Macrocyclics is an exhibitor at the 2025 SNMMI Annual Meeting, located in New Orleans, LA from June 21 to June 24. Ratio will also have representatives in attendance and will host a networking event for current and potential Macropa users. About Macrocyclics Macrocyclics, Inc., founded in 1995 with headquarters in Plano, Texas, is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. A subsidiary of Orano Med, the company stocks a catalog of products dedicated to chelation technology including bifunctional chelators, magnetic resonance agents, and reactive intermediates. The company supports rapid advancements in the field through its GMP compliant quality system, custom small molecule synthesis capabilities, and expertise in analytical development and characterization. For more information about the company, please visit: About Ratio Therapeutics Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials this year. Please visit for more information and follow us on Twitter (X) and LinkedIn. For information regarding ordering Macropa, please contact Macrocyclics at info@ View original content to download multimedia: SOURCE Ratio Therapeutics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-05-2025
- Business
- Yahoo
CNL Team Recognized With CNIC 2024 Ecosystem Innovation Award for Production of Promising New Medical Isotope
'While Actinium-225 drugs have shown incredible potential to serve as a transformative cancer treatment, clinical trials and eventual drug approvals have been impeded by the tight supply scenario of Actinium-225,' commented Ram Mullur, CNL's Vice-President of Isotopes. 'More than seven years ago, CNL set out to address that challenge with the generator route of production of Actinium-225, and we are now moving ever-closer to industrial-scale production. This was enabled through the services and products provided by our collaborators, including the Sylvia Fedoruk Centre, and Advanced Cyclotron Systems. This achievement is also in support of Actineer, which is a joint venture founded in 2023 by ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and CNL. On behalf of CNL, I want to thank the CNIC for recognizing CNL, our collaborators and partners, and the people who are working so hard to bring this vision to life.' The CNIC Awards are an annual celebration of the growth and success of Canadian isotope industry and the contributions and innovations of its members and leading Canadian individuals in government and industry. CNIC provides a platform for its community to nominate individuals and organizations who have demonstrated leadership and championed advocacy in the industry. Receiving the Ecosystem Innovation Award, which recognizes a major milestone or initiative in Canada's isotope industry, recognizes CNL's ongoing efforts to establish this first-of-a-kind production process in Canada, which brings a significant increase in the quantity of this material to market, and unlocks further research and clinical trials. CHALK RIVER, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, is pleased to announce that it has been recognized by the Canadian Nuclear Isotope Council (CNIC) alongside the Sylvia Fedoruk Centre and Advanced Cyclotron Systems Inc. for being the first in Canada to produce Actinium-225, a promising new medical isotope in the fight against cancer, using a cyclotron and Radium-226 targets. The team was honoured with this year's CNIC Ecosystem Innovation Award at the annual awards ceremony held in Ottawa, Ontario on April 15 th . Canadian Nuclear Isotope Council honours CNL, Sylvia Fedoruk Centre and Advanced Cyclotron Systems for first cyclotron irradiation of Radium-226 to produce Actinium-225 in Canada Story Continues 'The Fedoruk Centre is proud to participate in this achievement with CNL. The work depended on access to the Saskatchewan Cyclotron Facility, which is owned by the University of Saskatchewan and operated by the Fedoruk Centre. Together, we have advanced the production of an exciting new medical isotope here in Canada,' commented John Root, Executive Director of the Fedoruk Centre. 'We must thank the federal and provincial governments who funded the cyclotron and infrastructure to make this innovation possible.' 'The first demonstration of Actinium-225 production by CNL using ACSI's TR-24 Cyclotron and targetry system is an important milestone for both organisations. I believe that we will continue this successful collaboration in developing technology that will help in achieving worldwide reliable supply of Actinium-225,' stated Richard Eppich, President and CEO of ACSI. CNL is currently working as part of a network of organizations to establish a reliable, industrial-scale production process for Actinium-225. 'CNL has come a long way in the last seven years, and this award recognizes all of the hard work we have put in to help achieve this unmet need in the radiopharmaceutical industry,' added Mullur. 'But I am pleased to say that we are just getting started, and continue to refine, optimize and improve all aspects of the production process, from development through to the extraction and distribution of the final product. And with each step, our optimism continues to grow that this isotope has the potential to serve as a safe and effective treatment for a variety of cancers.' To learn more about CNL, including its work to produce Actinium-225, please visit About CNL As Canada's premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance – restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions. To learn more about CNL, please visit About the Sylvia Fedoruk Centre The Fedoruk Centre is a not-for-profit corporation with the University of Saskatchewan (USask) as its sole member and an independent board of directors appointed by the USask board of governors. The Fedoruk Centre board is responsible for providing high-level strategic direction and oversight of Fedoruk Centre operations. For more information about the Fedoruk Centre, visit: About Advanced Cyclotron Systems Inc. Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production and distribution of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada. ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market. The versatility, high beam current and exceptional quality of ACSI cyclotrons are the reasons why many of the world's most prestigious universities and research centers, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs. ACSI headquarters and manufacturing facility is located in Richmond, BC, Canada. For more information, please visit CNL Contact: Philip Kompass Director, Corporate Communications 1-866-886-2325 media@ Sylvia Fedoruk Centre Contact: Daniel Hallen USask Media Relations 306-966-6922 Advanced Cyclotron Systems Inc. Contact Alex Zyuzin Director of Research & Business Development azyuzin@ A photo accompanying this announcement is available at
Yahoo
24-04-2025
- Business
- Yahoo
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a distinctive portfolio of differentiated and highly targeted radiopharmaceuticals, today announced the signing of a supply agreement for Actinium-225 (Ac-225) to support the development of Alpha-9's radiopharmaceutical programs. Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by ActineerTM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories. Actineer is advancing cutting-edge technologies to secure and expand its supply chain and produce industrial-scale quantities of Ac-225 at rapid speed to meet the growing global demand. Further contract details have not been disclosed. 'This agreement strengthens our ongoing collaboration with Alpha-9 and reaffirms our mission to supply Actinium-225 to companies pioneering novel radiopharmaceuticals for high unmet need cancer indications,' said Dr. Andrew Cavey, CEO of ITM. 'We deeply value Alpha-9's continued trust in our capabilities to produce industrial-scale radioisotopes, supporting the development of breakthrough treatments that can potentially improve the lives of patients with cancer worldwide.' Ac-225 is a rare medical radioisotope used in radiopharmaceuticals to treat various cancer indications. It emits high-energy alpha particles with a short penetration range in tissue, enabling precise targeting of tumor cells. Studies with Ac-225 have shown it to cause double-stranded DNA breaks in cancer cells, leading to their destruction1. Its unique qualities along with its natural scarcity and manufacturing complexities make Ac-225 a highly sought after resource. With a comparatively short half-life of approximately ten days2, Ac-225 requires a highly sophisticated manufacturing and distribution network worldwide. 'With its global strength in providing high-quality radioisotopes including. Lutetium-177 and their growing capabilities for the production of Actinium-225, ITM is a valued partner as we progress our pipeline of clinical and discovery programs to meet the needs of cancer patients,' said Alison Fleming Ph.D., COO of Alpha-9 Oncology. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. About Actineer, Inc. is a joint venture company between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM) dedicated to advancing Ac-225 technologies, quickly securing supply, and producing industrial-scale quantities of this valuable, rare medical radioisotope for the treatment of cancer. Founded in October 2023, Actineer™ Inc. together with its strong supply chain collaborators seeks to progress Ac-225 development, production, and processing technologies. It has established short-term production capabilities that is expected to lead to significantly boosting international supplies, while working long-term towards the construction of a new Actinium Production Facility (APF) in Canada. The joint venture's mission is to fulfil the unmet global manufacturing and production needs of this coveted radioisotope with significant potential in the fight against cancer. About Alpha-9 Oncology Oncology Inc. is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. For more information, please visit ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Alpha-9 ContactCorporate CommunicationsStephen MitchenerPhone: +1 617 865 1004Email: smitchener@ 1Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. PMID: 38773983; PMCID: PMC11103494. 2Hooijman, E.L., Radchenko, V., Ling, S.W. et al. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI radiopharm. chem. 9, 9 (2024). Attachment 20252404_ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225Sign in to access your portfolio
